Tradestie Institutional Equity Comparison Engine

ROM vs SBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ROM Overall Edge

ROM Captures Institutional Edge (1โ€“1 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ProShares Ultra Technology (ROM) driven by superior Options & Structure while SBIO counters with relative strength in Momentum & Technical. Fundamentally, ROM trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SBIO at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ROM sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against SBIO sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ROM N/M vs SBIO N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner SBIO
1Y +15.9% vs +19.0% ยท 52W Pos 38% vs 35%
Options & Structure Winner ROM
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (6th %ile IV)
ROM NYSE Arca
ProShares Ultra Technology
Institutional Equity
$109.39
-6.72% 1D
Market Cap N/A
1M Return -21.37%
1Y Return +15.87%
Forward P/E N/M
Unified AI Score
48.9 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
SBIO NYSE Arca
ALPS Medical Breakthroughs ETF
Institutional Equity
$53.87
-3.17% 1D
Market Cap N/A
1M Return +7.48%
1Y Return +19.0%
Forward P/E N/M
Unified AI Score
46.4 / 100 HOLD
Tech 48.0 Fund 51.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ROM +15.87% SBIO +19.0% Spread: +3.13 pp (SBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ROM TTM Op. Margin: N/A SBIO TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ROM vs SBIO. Trailing 12-month operating profitability (ROM N/A vs SBIO N/A) and valuation multiples (ROM N/M vs SBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ROM (2) vs SBIO (1)
Institutional Metric ROM SBIO Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 38% ($71โ€“$172) 35% ($45โ€“$71) Stronger Trend ROM
Beta / 30D Volatility Risk Regime 3.65ฮฒ ยท 89% Vol 1.21ฮฒ ยท 44% Vol Lower Realized Risk SBIO
Unified Institutional Score Composite Signal 48.9 / 100 (HOLD) 46.4 / 100 (HOLD) Higher Composite ROM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ROM vs SBIO Buy Guide
ROM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ROM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live SBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ROM nor SBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.